Evidence map›Paper›PMID 34212761›Full record

ArticleJournal of the American Heart Association2021

Double Deletion of Angiotensin II Type 2 and Mas Receptors Accelerates Aging-Related Muscle Weakness in Male Mice.

Hikari Takeshita, Koichi Yamamoto, Masaki Mogi, Yu Wang, Yoichi Nozato, Taku Fujimoto, Serina Yokoyama, Kazuhiro Hongyo, Futoshi Nakagami, Hiroshi Akasaka and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Hikari TakeshitaDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Koichi YamamotoDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Masaki MogiDepartment of Pharmacology Ehime University Graduate School of Medicine Ehime Japan.
Yu WangDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Yoichi NozatoDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Taku FujimotoDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Serina YokoyamaDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Kazuhiro HongyoDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Futoshi NakagamiDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Hiroshi AkasakaDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Yoichi TakamiDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Yasushi TakeyaDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Ken SugimotoDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
Masatsugu HoriuchiDepartment of Molecular Cardiovascular Biology and Pharmacology Ehime University Graduate School of Medicine Ehime Japan.
Hiromi RakugiDepartment of Geriatric and General Medicine Osaka University Graduate School of Medicine Suita Japan.
The University of Osaka · JPEhime University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background The activation of AT2 (angiotensin II type 2 receptor ) and Mas receptor by angiotensin II and angiotensin-(1-7), respectively, is the primary process that counteracts activation of the canonical renin-angiotensin system (RAS). Although inhibition of canonical RAS could delay the progression of physiological aging, we recently reported that deletion of Mas had no impact on the aging process in mice. Here, we used male mice with a deletion of only AT2 or a double deletion of AT2 and Mas to clarify whether these receptors contribute to the aging process in a complementary manner, primarily by focusing on aging-related muscle weakness. Methods and Results Serial changes in grip strength of these mice up to 24 months of age showed that AT2/Mas knockout mice, but not AT2 knockout mice, had significantly weaker grip strength than wild-type mice from the age of 18 months. AT2/Mas knockout mice exhibited larger sizes, but smaller numbers and increased frequency of central nucleation (a marker of aged muscle) of single skeletal muscle fibers than AT2 knockout mice. Canonical RAS-associated genes, inflammation-associated genes, and senescence-associated genes were highly expressed in skeletal muscles of AT2/Mas knockout mice. Muscle angiotensin II content increased in AT2/Mas knockout mice. Conclusions Double deletion of AT2 and Mas in mice exaggerated aging-associated muscle weakness, accompanied by signatures of activated RAS, inflammation, and aging in skeletal muscles. Because aging-associated phenotypes were absent in single deletions of the receptors, AT2 and Mas could complement each other in preventing local activation of RAS during aging.

Indexed as

Muscle StrengthAge FactorsAnimalsFibrosisGene Expression RegulationGenetic Predisposition to DiseaseHand StrengthInflammation MediatorsMaleMiceMice, Inbred C57BLMice, KnockoutMuscle, SkeletalMuscle WeaknessPhenotypeProto-Oncogene MasAgtr2 protein, mouseInflammation MediatorsProto-Oncogene MasProto-Oncogene ProteinsReceptor, Angiotensin, Type 2Receptors, G-Protein-Coupledagingangiotensin II type 2 receptorMas receptormusclerenin‐angiotensin system

Identifiers

PMID34212761
PMCPMC8403326
OpenAlexW3173933823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.